Filing Flows

Filing Flows › Cartesian Therapeutics (RNAC) › Next earnings date

Cartesian Therapeutics (RNAC) earnings: beat the estimate

Cartesian Therapeutics (RNAC) reported on Nov 5, 2026 and beat the EPS estimate: −$0.85 against −$1.01 (+16.1%). It beat the EPS estimate in 20% of the quarters on record.

Last result+16.1% vs estimate
Beat rate20%

The last report

Cartesian Therapeutics reported revenue of $78K for the first quarter 2026 (-93% Y/Y), net loss $39.2M. How it makes money → · Every quarter →

Cartesian Therapeutics: EPS against the estimate, last 5 reportsCartesian Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.63−$0.73Nov 25−$0.79−$2.71Mar 26−$0.70−$0.95Apr 26−$0.65−$0.96Aug 26−$1.01−$0.85Nov 26
Latest (Nov 26): Estimate −$1.01, Reported −$0.85.

Cartesian Therapeutics' latest quarter

Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.

Questions

Did Cartesian Therapeutics beat earnings?

Cartesian Therapeutics (RNAC) reported on Nov 5, 2026 and beat the EPS estimate: −$0.85 against −$1.01 (+16.1%).

When does RNAC report earnings?

The next date is not set yet.

Does Cartesian Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.